AZD9291 (Osimertinib) is a highly potent and selective EGFR tyrosine kinase inhibitor that irreversibly binds to the catalytically active center of EGFR and inhibits its activity, which is highly effective in advanced NSCLC treatment [5, 6]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.